GF 1012
Alternative Names: GF-1012Latest Information Update: 02 Jan 2023
Price :
$50 *
At a glance
- Originator GenFleet Therapeutics
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haematological malignancies; Solid tumours
Most Recent Events
- 30 Dec 2022 Discontinued - Preclinical for Haematological malignancies in China (unspecified route) (GenFleet Therapeutics pipeline, December 2022)
- 30 Dec 2022 Discontinued - Preclinical for Solid tumours in China (unspecified route) (GenFleet Therapeutics pipeline, December 2022)
- 01 Aug 2022 Preclinical trials in Haematological malignancies in China (unspecified route) (GenFleet Therapeutics pipeline, August 2022)